Mabion S.A. (FRA:272)
1.904
-0.020 (-1.04%)
At close: Jan 30, 2026
Mabion Employees
As of December 31, 2024, Mabion had 213 total employees, including 206 full-time and 7 part-time employees. The number of employees decreased by 34 or -13.77% compared to the previous year.
Employees
213
Change (1Y)
-34
Growth (1Y)
-13.77%
Revenue / Employee
€16,529
Profits / Employee
€66,175
Market Cap
31.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 213 | -34 | -13.77% | 206 | 7 |
| Dec 31, 2023 | 247 | -8 | -3.14% | 241 | 6 |
| Dec 31, 2022 | 255 | 11 | 4.51% | 248 | 7 |
| Dec 31, 2021 | 244 | 31 | 14.55% | 244 | 0 |
| Dec 31, 2020 | 213 | - | - | 213 | 0 |
Related Stocks
Employee RankingsMabion News
- 5 years ago - Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer - GlobeNewsWire
- 5 years ago - Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease - GlobeNewsWire
- 6 years ago - GAMCO Investors Exits Viacom, Spark Therapeutics - GuruFocus
- 6 years ago - Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition - Benzinga
- 6 years ago - Roche to complete $4.3 billion Spark deal as regulators give all clear - Reuters
- 6 years ago - U.S. antitrust enforcers give Roche approval to buy Spark Therapeutics - Reuters
- 6 years ago - Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product - GlobeNewsWire
- 6 years ago - FTC staff recommends approval of Roche deal for Spark: report - Reuters